Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.

Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R.

J Psychopharmacol. 2011 Apr;25(4):439-52. doi: 10.1177/0269881110378371. Epub 2010 Jul 19. Erratum in: J Psychopharmacol. 2011 Jun;25(6):852.

2.

A randomized, controlled pilot study of MDMA (± 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD).

Oehen P, Traber R, Widmer V, Schnyder U.

J Psychopharmacol. 2013 Jan;27(1):40-52. doi: 10.1177/0269881112464827. Epub 2012 Oct 31.

PMID:
23118021
3.

Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study.

Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Martin SF, Yazar-Klosinski B, Michel Y, Brewerton TD, Doblin R.

J Psychopharmacol. 2013 Jan;27(1):28-39. doi: 10.1177/0269881112456611. Epub 2012 Nov 20.

4.

The Psychopharmacology of ±3,4 Methylenedioxymethamphetamine and its Role in the Treatment of Posttraumatic Stress Disorder.

Amoroso T.

J Psychoactive Drugs. 2015 Nov-Dec;47(5):337-44. doi: 10.1080/02791072.2015.1094156. Epub 2015 Nov 18. Review.

PMID:
26579955
5.

Effects of 3,4-Methylenedioxymethamphetamine on Patient Utterances in a Psychotherapeutic Setting.

Corey VR, Pisano VD, Halpern JH.

J Nerv Ment Dis. 2016 Jul;204(7):519-23. doi: 10.1097/NMD.0000000000000499.

PMID:
26998697
6.

D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial.

Difede J, Cukor J, Wyka K, Olden M, Hoffman H, Lee FS, Altemus M.

Neuropsychopharmacology. 2014 Apr;39(5):1052-8. doi: 10.1038/npp.2013.317. Epub 2013 Nov 12.

7.

How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale.

Johansen PØ, Krebs TS.

J Psychopharmacol. 2009 Jun;23(4):389-91. doi: 10.1177/0269881109102787. Epub 2009 Mar 9.

PMID:
19273493
8.

MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder.

Bouso JC, Doblin R, Farré M, Alcázar MA, Gómez-Jarabo G.

J Psychoactive Drugs. 2008 Sep;40(3):225-36.

PMID:
19004414
9.

Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial.

Davidson J, Baldwin D, Stein DJ, Kuper E, Benattia I, Ahmed S, Pedersen R, Musgnung J.

Arch Gen Psychiatry. 2006 Oct;63(10):1158-65.

PMID:
17015818
10.

Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial.

Dunlop BW, Rothbaum BO, Binder EB, Duncan E, Harvey PD, Jovanovic T, Kelley ME, Kinkead B, Kutner M, Iosifescu DV, Mathew SJ, Neylan TC, Kilts CD, Nemeroff CB, Mayberg HS.

Trials. 2014 Jun 21;15:240. doi: 10.1186/1745-6215-15-240.

11.

Potential Psychiatric Uses for MDMA.

Yazar-Klosinski BB, Mithoefer MC.

Clin Pharmacol Ther. 2017 Feb;101(2):194-196. doi: 10.1002/cpt.565.

12.

Effectiveness of deep transcranial magnetic stimulation combined with a brief exposure procedure in post-traumatic stress disorder--a pilot study.

Isserles M, Shalev AY, Roth Y, Peri T, Kutz I, Zlotnick E, Zangen A.

Brain Stimul. 2013 May;6(3):377-83. doi: 10.1016/j.brs.2012.07.008. Epub 2012 Aug 18.

PMID:
22921765
13.

Narrative exposure therapy versus interpersonal psychotherapy. A pilot randomized controlled trial with Rwandan genocide orphans.

Schaal S, Elbert T, Neuner F.

Psychother Psychosom. 2009;78(5):298-306. doi: 10.1159/000229768. Epub 2009 Jul 24.

PMID:
19628958
14.

3,4-Methylenedioxymethamphetamine's (MDMA's) Impact on Posttraumatic Stress Disorder.

White CM.

Ann Pharmacother. 2014 Jul;48(7):908-915. Epub 2014 Apr 16.

PMID:
24740469
15.

A pilot study of interpersonal psychotherapy for posttraumatic stress disorder.

Bleiberg KL, Markowitz JC.

Am J Psychiatry. 2005 Jan;162(1):181-3.

PMID:
15625219
16.

A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder: a preliminary study.

Davis LL, Jewell ME, Ambrose S, Farley J, English B, Bartolucci A, Petty F.

J Clin Psychopharmacol. 2004 Jun;24(3):291-7.

PMID:
15118483
17.

Low-dose cortisol for symptoms of posttraumatic stress disorder.

Aerni A, Traber R, Hock C, Roozendaal B, Schelling G, Papassotiropoulos A, Nitsch RM, Schnyder U, de Quervain DJ.

Am J Psychiatry. 2004 Aug;161(8):1488-90.

PMID:
15285979
18.

Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial.

Davidson JR, Weisler RH, Butterfield MI, Casat CD, Connor KM, Barnett S, van Meter S.

Biol Psychiatry. 2003 Jan 15;53(2):188-91.

PMID:
12547477
19.

A randomized, double-blind, placebo-controlled trial to assess the efficacy of topiramate in the treatment of post-traumatic stress disorder.

Mello MF, Yeh MS, Barbosa Neto J, Braga LL, Fiks JP, Mendes DD, Moriyama TS, Valente NL, Costa MC, Mattos P, Bressan RA, Andreoli SB, Mari JJ.

BMC Psychiatry. 2009 May 29;9:28. doi: 10.1186/1471-244X-9-28.

20.

The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans.

Tancer M, Johanson CE.

Psychopharmacology (Berl). 2007 Jan;189(4):565-73. Epub 2006 Oct 18.

PMID:
17047932

Supplemental Content

Support Center